Jounce Therapeutics Inc (JNCE.OQ)
JNCE.OQ on NASDAQ Stock Exchange Global Select Market
19.46USD
20 Apr 2018
19.46USD
20 Apr 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$19.46
$19.46
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
111,853
111,853
52-wk High
$29.29
$29.29
52-wk Low
$11.05
$11.05
About
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on... (more)
Overall
| Beta: | -- |
| Market Cap(Mil.): | $554.71 |
| Shares Outstanding(Mil.): | 32.19 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| JNCE.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 7,903.67 | 84.02 | 32.74 |
| EPS (TTM): | 0.00 | -- | -- |
| ROI: | 4.65 | 1.58 | 14.38 |
| ROE: | 0.82 | 2.41 | 16.07 |
BRIEF-Jounce Therapeutics Files For Mixed Shelf Of Up To $250 Mln
* JOUNCE THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION - SEC FILING
BRIEF-Jounce Therapeutics Q4 Loss Per Share $0.29
* JOUNCE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS
BRIEF-Jounce Therapeutics reports Q3 loss $0.13/shr
* Jounce Therapeutics reports third quarter 2017 financial results
Competitors
| Price | Chg | |
|---|---|---|
| Bristol-Myers Squibb Co (BMY.N) | $51.17 | -- |
| Bristol-Myers Squibb Co (BMYMP.PK) | $1,306.55 | -- |
| Merck & Co., Inc. (MRK.N) | $60.19 | +1.36 |
| Merck KGaA (MRCG.DE) | €82.02 | 0.00 |
| Pfizer Inc. (PFE.N) | $36.77 | +0.14 |
| Incyte Corporation (INCY.OQ) | $68.80 | +0.37 |
| Regeneron Pharmaceuticals Inc (REGN.OQ) | $314.25 | -- |
| Sanofi SA (SASY.PA) | €65.80 | +0.52 |
| TESARO Inc (TSRO.OQ) | $51.58 | -- |
| Novartis AG (NOVN.S) | CHF75.92 | -0.16 |
Estimates